TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04271384

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Combined neoadjuvant therapy consisting of nivolumab + SABR
Study: NCT04323644

Intervention type: PROCEDURE
Intervention: Surgery
Description: Emergency or elective surgery
Study: NCT02675140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZENTEL
Description: Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZENTEL and Vitamin A Soft Capsules
Description: Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
Study: NCT05181813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ginge-Cal
Description: Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metapex
Description: Fill the infected root canal of of primary teeth with Metapex
Study: NCT02562040

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Description: Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
Study: NCT01758081

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study: NCT03477630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: intra-articular infiltration of 8 ml of autologous PRP every 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: intra-articular infiltration of a single dose of HA
Study: NCT01758081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Study: NCT05024838

Intervention type: OTHER
Intervention: Machine learning methods
Description: This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
Study: NCT04297163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Remote CPAP monitoring, mobile app and voice mail
Study: NCT01758081

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fish oil placebo
Study: NCT03809793

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: VO2 Max
Description: Assessment of maximum aerobic capacity.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsies
Description: Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
Study: NCT01190176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gynaecological follow-up
Description: Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
Study: NCT04297163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In Hospital
Description: Face-to-face follow up
Study: NCT03302611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity-based Interventions
Description: Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity-based Interventions
Description: Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
Study: NCT03363555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized monoclonal immunoglobulin.
Study: NCT01243983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX211
Description: Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX211
Description: Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks
Study: NCT03601403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhaler technique
Description: The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
Study: NCT01804205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
Study: NCT00615316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaraná
Description: Guaraná extract 75mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tab/d
Study: NCT03061591

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wholistic Turmeric capsules
Description: Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT06321653

Intervention type: RADIATION
Intervention: Hypofractionated radiotherapy scheme
Description: Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
Study: NCT02542254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: 40 micrograms ipratropium administered using a pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium
Description: 40 micrograms ipratropium administered using a pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: 6 mg RPL554 administered using a nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: 6 mg RPL554 administered using a nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: 6 mg RPL554 administered using a nebuliser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol matched placebo
Description: Placebo pMDI
Study: NCT01014156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoprostenol
Description: titration up to 4 ng/kg/min
Study: NCT02560415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Gaming Open Library for Intervention in Autism at Home plus Treatment as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Treatment as usual
Study: NCT04682964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
Description: Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
Study: NCT03957057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Intravenous iron carboxymaltose application
Study: NCT02542254

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium matched placebo
Description: Placebo pMDI
Study: NCT03957057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: Inravenous iron isomaltoside application
Study: NCT02542254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium matched placebo
Description: Placebo pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPL554 matched placebo
Description: Nebulised placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RPL554 matched placebo
Description: Nebulised placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPL554 matched placebo
Description: Nebulised placebo
Study: NCT03768635

Intervention type: OTHER
Intervention: necrotizing external otitis
Description: description of necrotizing external otitis
Study: NCT00918684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10mg tab daily
Study: NCT03957057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Oral ferrous sulphate application
Study: NCT04422132

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5 days Radiation Therapy (32.5 Gy in 5 fractions)
Description: Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 20 days Radiation therapy (55 Gy in 20 fractions)
Description: Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
Study: NCT03809793

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Biopsies
Description: Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox 250 MG
Description: Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
Study: NCT01856283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300mg BID
Description: Nilotinib
Study: NCT01190176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
Study: NCT03876548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cadexomer Iodine Gel
Description: Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
Study: NCT03216291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback therapy
Description: Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Biofeedback therapy
Description: Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
Study: NCT03189511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin 40 mg twice daily per mouth for 14 days.
Study: NCT03416933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
Study: NCT06042660

Intervention type: OTHER
Intervention: the prevalence of comorbid conditions
Description: analysis of history of comorbidities at the time of CML diagnosis
Study: NCT03512223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous and Perineural Dexamethasone for Brachial Plexus Block
Study: NCT02128308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin and Streptomycin added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Kanamycin added
Study: NCT02134821

Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis
Description: decompression with or without fusion for lumbar spinal stenosis

Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis
Description: decompression with or without fusion for lumbar spinal stenosis
Study: NCT00373256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab 10 mg/kg IV every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
Study: NCT01957059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 2
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 3
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Group 4
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 1 (COMPLETED)
Description: All doses of BMN053 have been administered as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing Extension
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
Study: NCT02256943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 100 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 100 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg single dose
Study: NCT03346902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Injection of EB-001 into area of scarring (forehead)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Injection of Saline into area of scarring (forehead)
Study: NCT02741687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
Study: NCT03153293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: a Single IVT Injection
Study: NCT03701178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK
Description: milled BioHPP PEEK in a new material can be used as a dental restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioHPP PEEK
Description: milled BioHPP PEEK in a new material can be used as a dental restoration
Study: NCT01855568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-dose Methotrexate
Description: Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-dose methotrexate protocol
Description: Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment.
Study: NCT02245893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction internal fixation (ORIF)
Description: The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction internal fixation (ORIF)
Description: The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
Study: NCT02181621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iodosorb
Description: Cadexomer iodine gel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Solosite gel
Description: Hydrogel
Study: NCT02697929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study: NCT04143438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EOS 3D imaging protocol pre- and post-surgery
Description: Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
Study: NCT02319083

Intervention type: PROCEDURE
Intervention: Coronary artery bypass surgery
Description: Patients will undergo coronary artery bypass grafting
Study: NCT04534725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Description: intravenous infusion